{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:50:47Z","timestamp":1791355847363,"version":"4.3.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.leukres.2014.04.006","type":"journal-article","created":{"date-parts":[[2014,4,28]],"date-time":"2014-04-28T01:45:10Z","timestamp":1398649510000},"page":"1165-1172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"38","author":[{"given":"Julio C.","family":"Chavez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongphil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binglin","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Dalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Anasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.04.006_bib0005","series-title":"SEER cancer statistics review, 1975\u20132005","first-page":"1975","author":"Ries","year":"2008"},{"key":"10.1016\/j.leukres.2014.04.006_bib0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/107327481201900106","article-title":"Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia","volume":"19","author":"Carballido","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.leukres.2014.04.006_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.04.006_bib0020","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.04.006_bib0025","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.04.006_bib0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.04.006_bib0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.20.1.205","article-title":"Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed","volume":"20","author":"Keating","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.04.006_bib0040","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/bmt.2012.71","article-title":"Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis","volume":"47","author":"Kharfan-Dabaja","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2014.04.006_bib0045","first-page":"275","article-title":"Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG","volume":"7","author":"Michallet","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2014.04.006_bib0050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bmt.1700850","article-title":"Induction of graft-versus-leukemia effect in a patient with chronic lymphocytic leukemia","volume":"20","author":"deMagalhaes-Silverman","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2014.04.006_bib0055","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.bmt.1705130","article-title":"Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease","volume":"36","author":"Toze","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2014.04.006_bib0060","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.leu.2402530","article-title":"Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia","volume":"16","author":"Dreger","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.04.006_bib0065","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.04.006_bib0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/imt.13.31","article-title":"Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies","volume":"5","author":"El-Jurdi","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.leukres.2014.04.006_bib0075","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.04.006_bib0080","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/JCO.2008.16.2982","article-title":"Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis","volume":"26","author":"Schetelig","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.04.006_bib0085","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.04.006_bib0090","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.leu.2403745","article-title":"Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis","volume":"19","author":"Dreger","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.04.006_bib0095","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/107327481201900107","article-title":"Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens","volume":"19","author":"Kharfan-Dabaja","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.leukres.2014.04.006_bib0100","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.23671","article-title":"Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia","volume":"113","author":"Kharfan-Dabaja","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.04.006_bib0105","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.04.006_bib0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.04.006_bib0115","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2014.04.006_bib0120","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2010.01.010","article-title":"A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis","volume":"16","author":"Perkins","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.leukres.2014.04.006_bib0125","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3324\/haematol.2012.067140","article-title":"A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation","volume":"97","author":"Pidala","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.04.006_bib0130","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.04.006_bib0135","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.04.006_bib0140","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2014.04.006_bib0145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/bmt.2008.305","article-title":"New classification of chronic GVHD: added clarity from the consensus diagnoses","volume":"43","author":"Arora","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2014.04.006_bib0150","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.bbmt.2013.04.020","article-title":"Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting","volume":"19","author":"Kharfan-Dabaja","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.leukres.2014.04.006_bib0155","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.leukres.2014.04.006_bib0160","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.leukres.2014.04.006_bib0165","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.leukres.2014.04.006_bib0170","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12185-010-0747-x","article-title":"Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications","volume":"93","author":"Pidala","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2014.04.006_bib0175","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2007-04-067215","article-title":"Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease","volume":"110","author":"Brunstein","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.04.006_bib0185","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.bmt.1701779","article-title":"Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection","volume":"23","author":"Thiede","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2014.04.006_bib0190","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","volume":"116","author":"Dreger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.04.006_bib0195","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2012.228","article-title":"Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome","volume":"27","author":"Brown","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.04.006_bib0200","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1002\/cncr.26091","article-title":"Nonmyeloablative allogeneic stem cell transplantation in relapsed\/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome","volume":"117","author":"Khouri","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.04.006_bib0205","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2006.06.004","article-title":"Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia","volume":"12","author":"Brown","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.leukres.2014.04.006_bib0215","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1158\/1078-0432.CCR-05-0941","article-title":"Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)","volume":"11","author":"Caballero","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.04.006_bib0220","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2141.2012.09239.x","article-title":"Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia","volume":"159","author":"Jaglowski","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2014.04.006_bib0225","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2141.2012.09170.x","article-title":"Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort","volume":"158","author":"Toze","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2014.04.006_bib0230","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2014.04.006_bib0235","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/blood-2012-11-469627","article-title":"TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial","volume":"121","author":"Dreger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.04.006_bib0240","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.bbmt.2009.01.021","article-title":"Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes","volume":"15","author":"van Besien","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.leukres.2014.04.006_bib0245","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2005.04.569","article-title":"Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia","volume":"23","author":"Sorror","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.04.006_bib0250","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614001179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614001179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T18:57:38Z","timestamp":1565377058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614001179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0145212614001179"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.04.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}